EU Extends Approval Period for 20 Active Substances, Including Fluometuron
In a recent development, the European Union (EU) has announced the extension of the approval period for 20 active substances, including Fluometuron. This decision was made through Regulation (EU) 2024/1206, which was published by the EU Commission on April 30, 2024. The regulation will come into effect 20 days after its publication.
The European Union has taken a significant step by extending the approval period for several active substances used in various applications. Regulation (EU) 2024/1206, published by the EU Commission on April 30, 2024, outlines the revised approval deadlines for 20 substances.
Among the substances affected by this extension are Fluometuron, 6-benzyladenine, dodine, 1-decanol, sintofen, aluminium sulfate, and prosulfuron. The approval period for these substances has been extended until July 15, 2026.
Additionally, the approval deadlines for quinmerac, zinc phosphide, orange oil, tembotrione, and sodium silver thiosulfate have been extended until December 31, 2026.
Furthermore, tau-fluvalinate, bupirimate, isoxaben, azadirachtin, lime sulphur, tebufenozide, dithianon, and hexythiazox will now have their approval periods extended until January 31, 2027.
This decision by the EU Commission aims to provide stakeholders with sufficient time to comply with the regulations and ensure the safe and responsible use of these active substances in various industries.
The extension of the approval period allows companies and manufacturers to continue using these substances in their products and applications while they work towards meeting the necessary regulatory requirements. It also provides an opportunity for further research and evaluation of their environmental and health impacts.
The EU's decision to extend the approval period for these active substances reflects its commitment to maintaining high standards of safety and sustainability in the use of chemicals and agricultural inputs. By carefully regulating the use of these substances, the EU aims to protect human health, safeguard the environment, and promote sustainable practices within its member states.
The European Union's recent decision to extend the approval period for 20 active substances, including Fluometuron, demonstrates its commitment to ensuring the safe and responsible use of chemicals. This measure provides stakeholders with additional time to comply with regulatory requirements and underscores the EU's dedication to protecting human health and the environment. By striking a balance between innovation and sustainability, the EU continues to play a crucial role in promoting the well-being of its citizens and the preservation of our planet.
2026-09-25
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Behind the Three Consecutive Titanium Dioxide Price Hikes, Sulfur and Sulfuric Acid Costs Are Rewriting the Pricing Floor
-
DKSH Expands Partnership with Assessa to Distribute Botanical Ingredients Across China
-
High Crude Prices Are Passing Through the Coatings Chain as More Than 20 Companies Launch Price Increases
-
Chung Lien Oil’s 8,000-Ton Soybean Oil BaP Scandal: NT$165 Million Fine, 401 Product Recalls, Source Still Unknown
-
U.S. 10% Temporary Tariff Expires, New Section 301 Tariffs Not Yet Implemented
-
U.S. Chemical Tariff Deadline Nears as the Industry Faces Cost Repricing and Supply-Chain Adjustment
-
EU Biocidal Data Protection Extension Raises the Stakes for Chemical Market Entry
-
EU Finalizes Anti-Dumping Duties on Chinese Adipic Acid as Chemical Trade Enters a Rule-Intensive Phase
-
Global Chemical Giants Accelerate Plant Closures and Layoffs as Industry Enters Structural Capacity Rationalization
-
European Diesel Crack Spread Hits Record $74.66 per Barrel as Global Refinery Outages Mount
Recommend Reading
-
India Raises Cancer Drug Price Caps by 50%
-
Pfizer Warns Germany Over Drug-Pricing Policy
-
New York Targets Additives and GRAS Disclosure
-
FDA Grants Accelerated Approval to Bristol Myers Squibb’s ZENBEXUS, Launching First CELMoD Therapy in Multiple Myeloma
-
Synthomer Sells Its Last Upstream Chemical Business
-
Business Society’s Aniline Market Outlook on September 9, 2026: Downward Trend
-
Business Society’s Market Outlook for Maleic Anhydride on August 19, 2026: Volatile
-
Business Society’s Market Outlook for Aniline on September 8, 2026: Weak and Volatile
-
Business Society’s DOP Market Outlook on August 20, 2026: Clearly Upward
-
Business Society’s Market Outlook for Phthalic Anhydride on September 9, 2026: Volatile and Bearish